证券代码：300573 证券简称：兴齐眼药 公告编号：2025-033 沈阳兴齐眼药股份有限公司 特此公告。 沈阳兴齐眼药股份有限公司 董事会 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）于2025年8月26日收到深 圳证券交易所（以下简称"深交所"）出具的《关于受理沈阳兴齐眼药股份有限 公司向特定对象发行股票申请文件的通知》（深证上审〔2025〕159号）。深交 所对公司报送的向特定对象发行股票的申请文件进行了核对，认为申请文件齐备， 决定予以受理。 公司本次向特定对象发行股票的事宜尚需通过深交所审核，并获得中国证券 监督管理委员会（以下简称"中国证监会"）同意注册后方可实施，最终能否通 过深交所审核并获得中国证监会同意注册的决定及时间仍存在不确定性。公司将 根据该事项进展情况及时履行信息披露义务，敬请广大投资者谨慎决策，注意投 资风险。 关于向特定对象发行股票申请获得深圳证券交易所受理的 公告 ...

Core Viewpoint - The company has shown significant growth in revenue and net profit in both 2024 and Q1 2025, driven by successful product launches and a strong pipeline in the ophthalmic drug sector [1][2][3]. Financial Performance - In 2024, the company achieved revenue of 1.943 billion yuan, a year-on-year increase of 32.42%, and a net profit of 338 million yuan, up 40.84% [1]. - For Q1 2025, the company reported revenue of 536 million yuan, representing a 53.24% year-on-year growth, and a net profit of 146 million yuan, which surged by 319.86% [2]. - The overall gross margin improved to 78.33% in 2024, with a further increase to 80.16% in Q1 2025 [3]. Cost Management - The company reduced its total expense ratio to 56.47% in 2024, down by 1.51 percentage points, and further decreased it to 47.26% in Q1 2025, a drop of 17.21 percentage points [3]. - Sales expense ratio decreased to 36.30% in 2024 and further to 31.34% in Q1 2025 [3]. Product Development and Market Position - The company’s product "Meioupin" is the first low-concentration atropine eye drops approved in China for delaying myopia progression in children, included in multiple clinical guidelines [4]. - The company is advancing its pipeline with several products in various stages of clinical trials, including drugs for dry eye syndrome and other ophthalmic conditions [5]. Investment Outlook - The company is projected to achieve revenues of 3.03 billion yuan, 4.04 billion yuan, and 5.07 billion yuan for 2025 to 2027, with respective year-on-year growth rates of 55.9%, 33.2%, and 25.6% [6]. - Net profit forecasts for the same period are 600 million yuan, 820 million yuan, and 1.05 billion yuan, with growth rates of 78.7%, 36.1%, and 28.1% respectively [6].